Gloria Brun, MD
Child & Adolescent Psychiatry · Greenville, TXNPI 1417088154
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 529 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,600, 3.8 times the $677 reported in 2019. Among child & adolescent psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 529 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$973
- Otsuka America Pharmaceutical, Inc.$887
- Vanda Pharmaceuticals Inc.$642
- Alkermes, Inc.$624
- plus $4K from 23 others
What the payments were for
- Food & beverage$9,92099%
- Education$1241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 106 | $1,526 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 79 | $1,485 |
| Teva Pharmaceuticals USA, Inc. | 49 | $973 |
| Otsuka America Pharmaceutical, Inc. | 45 | $887 |
| Vanda Pharmaceuticals Inc. | 27 | $642 |
| Alkermes, Inc. | 27 | $624 |
| Supernus Pharmaceuticals, Inc. | 19 | $429 |
| Ironshore Pharmaceuticals Inc. | 18 | $414 |
| Corium, LLC | 22 | $389 |
| Neurocrine Biosciences, Inc. | 11 | $326 |
| Tris Pharma Inc | 18 | $287 |
| Axsome Therapeutics, Inc. | 11 | $275 |
| E.r. Squibb & Sons, L.L.C. | 11 | $257 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $255 |
| Idorsia Pharmaceuticals US Inc | 11 | $226 |
| Johnson & Johnson | 11 | $206 |
| Noven Therapeutics, LLC | 8 | $135 |
| Eisai Inc. | 6 | $127 |
| Adlon Therapeutics L.p. | 8 | $124 |
| Almatica Pharma LLC | 7 | $114 |
| Lundbeck LLC | 4 | $80 |
| Avanir Pharmaceuticals, Inc. | 4 | $72 |
| OWP Pharmaceuticals, Inc. | 3 | $59 |
| Collegium Pharmaceutical, Inc. | 2 | $31 |
| Indivior Inc. | 1 | $27 |
| Bausch Health US, LLC | 1 | $25 |
| Avion Pharmaceuticals | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,044 in reported general payments places this provider in the 95th percentile of 301 child & adolescent psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 45 | $67,174 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $20,515 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 93 | $2,786 |
| Clonazepam | 134 | $2,006 |
| Duloxetine Hcl | 42 | $1,739 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 17 | $1,432 |
| Quetiapine Fumarate | 50 | $1,291 |
| Bupropion XlBupropion Hcl | 60 | $1,141 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 37 | $947 |
| Trazodone Hcl | 67 | $915 |
| Aripiprazole | 23 | $832 |
| Buspirone Hcl | 41 | $812 |
| Lamotrigine | 37 | $644 |
| Lurasidone Hcl | 22 | $632 |
| Escitalopram Oxalate | 31 | $339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,526 | $67,17445 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $72 | $20,51513 claims |
| Almatica Pharma LLCSertraline Hcl | $114 | $30047 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 301 child & adolescent psychiatry providers in Texas.
Other child & adolescent psychiatry in Greenville
- Alain KaticBellaire$106K
- Steven PliszkaSan Antonio$59K
- Mary Garcia HolguinSan Antonio$24K
- John SteffekSpring$14K
- Robert MosquedaEdinburg$13K
- Mudassar TariqSugar Land$9K
- Charles PryzantDallas$9K
- Mehvesh AfrinaPlano$8K
- Kishore SunkaraHurst$8K
- Moses RamosDesoto$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.